News und Analysen
![DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
DGAP-News: Abivax verschiebt Veröffentlichung des Referenzdokuments ('Universal Registration Document', URD)
![DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
DGAP-News: Abivax postpones the publication of the yearly universal registration document ('URD')
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2019 und gibt Update zur Unternehmensentwicklung](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2019 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2019 und gibt Update zur Unternehmensentwicklung
![DGAP-News: Abivax 2019 Financial Results and Operations Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax 2019 Financial Results and Operations Update
DGAP-News: Abivax 2019 Financial Results and Operations Update
![DGAP-News: Abivax Finanzkalender 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-News: Abivax Finanzkalender 2020
DGAP-News: Abivax Finanzkalender 2020
![DGAP-News: Abivax 2020 Financial Communication Calendar](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-News: Abivax 2020 Financial Communication Calendar
DGAP-News: Abivax 2020 Financial Communication Calendar
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
![DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
![Sartorius Stedim Biotech SA: Information on Document Availability](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna
DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna
![DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien
DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien
![DGAP-News: Abivax erhält FDA-Genehmigung für den Start klinischer Studien mit ABX464 in den USA zur Behandlung mittelschwerer bis schwerer Colitis ulcerosa](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: Abivax erhält FDA-Genehmigung für den Start klinischer Studien mit ABX464 in den USA zur Behandlung mittelschwerer bis schwerer Colitis ulcerosa
DGAP-News: Abivax erhält FDA-Genehmigung für den Start klinischer Studien mit ABX464 in den USA zur Behandlung mittelschwerer bis schwerer Colitis ulcerosa
![DGAP-News: Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
DGAP-News: Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
![DGAP-News: ABIVAX: Finanzkalender 2020](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: ABIVAX: Finanzkalender 2020
DGAP-News: ABIVAX: Finanzkalender 2020
![Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
![Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
![GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration: https://mms.businesswire.com/media/20240319984906/en/2072888/5/Graph_1_ENG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEJhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--28a4f822849f533e3401084e17072d71a3457139/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Graph_1_ENG.jpg?locale=de)
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319984906/en/
Graph 1: Evolution of Best-Corrected Visual Acuity
![GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024: https://mms.businesswire.com/media/20240311531952/en/2062971/5/Figure_1_ENG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkpSYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8b27aa9b0d713ab517b775ca4be207a49e2348f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Figure_1_ENG.jpg?locale=de)
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311531952/en/
Figure 1. Visual Recovery (CRR from Nadir) Among